<DOC>
	<DOCNO>NCT02266550</DOCNO>
	<brief_summary>The aims phase I study define metabolism , excretion pharmacokinetics [ 14C ] -BIIL 284 BS administration single oral dose 25 mg [ 14C ] -BIIL 284 BS 6 healthy volunteer . Tolerability also assess .</brief_summary>
	<brief_title>Metabolism Pharmacokinetics 14C-BIIL 284 BS Healthy Volunteers</brief_title>
	<detailed_description />
	<criteria>Healthy male volunteer , range 30 55 year age inclusive Body weight 50 100 kg within ± 20 % ideal body weight No clinically significant abnormal physical finding screen examination would interfere objective study No clinically relevant abnormality result laboratory screening evaluation Normal ECG Normal Blood pressure ( 100 150 mmHg systolic 50 90 mmHg diastolic ) heart rate ( 50 90 beat per minute ) Able communicate well investigator comply requirement entire study Provision write informed consent participate show signature volunteer consent form Nonsmokers Medical examination laboratory test result judge clinical investigator differ significantly normal clinical value Known gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder Current disease central nervous system ( epilepsy ) psychiatric disorder ) Known history orthostatic hypotension , faint spell blackouts Chronic relevant acute infection Intake drug might influence result trial week previous start study Administration investigational drug period 3 month entry study ( 4 month previous drug new chemical entity ) A need medication within two week dose Existence surgical medical condition , judgement clinical investigator , might interfere absorption , distribution , metabolism excretion drug ( e.g . renal hepatic impairment ) Presence clinically relevant history allergy/hypersensitivity ( include drug allergy ) Blood loss donation within last 12 week ( ≥ 400 ml ) Serious adverse reaction/hypersensitivity drug Objection subject 's general practitioner his/her patient 's participation study Positive result drug screen list protocol , positive result hepatitis B surface antigen , Anti hepatitis B core antibody , Anti hepatitis C virus antibody human immunodeficiency test , Glucose 6 Phosphate Dehydrogenase Inability communicate cooperate investigator due language problem , poor mental development impair cerebral function Administration radiolabelled substance exposure significant radiation ( e.g . serial Xray , CT scan , barium meal , etc ) within past 12 month History recent drug abuse Volunteers drink 4 unit alcohol per day and/or consume alcohol 24 hour dose Participation excessive physical activity ( e.g . competitive sport ) within last week study</criteria>
	<gender>Male</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>